HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Chronic treatment with the D1 receptor antagonist, SCH 23390, and the D2 receptor antagonist, raclopride, in cebus monkeys withdrawn from previous haloperidol treatment. Extrapyramidal syndromes and dopaminergic supersensitivity.

Abstract
The effects of chronic treatment with dopamine (DA) D1 and D2 receptor antagonists were evaluated in eight cebus apella monkeys with mild oral dyskinesia after previous haloperidol treatment. SCH 23390 (D1 antagonist) was given daily to investigate the direct behavioural effect during long-term treatment and the subsequent supersensitivity to DA agonists. Raclopride (D2 antagonist) was investigated for comparison. All drugs were given subcutaneously. SCH 23390 and raclopride induced dystonic syndromes, catalepsy, sedation and reduced locomotor activity. The monkeys developed marked tolerance to the dystonic effect of SCH 23390, while they showed increased sensibility to the dystonic effect of raclopride. Baseline oral dyskinesia (24 h after injection) remained unchanged during D1 antagonist treatment, while it increased during D2 antagonist treatment. SCH 23390 induced supersensitivity to the oral dyskinesia- and grooming-inducing effects of SKF 81297 (D1 agonist) after 9 weeks, while the subsequent treatment with raclopride induced supersensitivity to the reactivity- and stereotypy-inducing effects of quinpirole (D2 receptor agonist) after 3 weeks. Because of the possibility of a carry-over effect (SKF 81297-induced oral hyperkinesia and grooming), other changes in raclopride-induced behaviours cannot be ruled out. The development of tolerance to the dystonic effect of SCH 23390 and the unchanged baseline oral dyskinesia during SCH 23390 treatment indicate an advantageous profile of side effects of DA D1 receptor blockade.
AuthorsH Lublin, J Gerlach, L Peacock
JournalPsychopharmacology (Psychopharmacology (Berl)) Vol. 112 Issue 2-3 Pg. 389-97 ( 1993) ISSN: 0033-3158 [Print] Germany
PMID7871047 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Benzazepines
  • Dopamine D2 Receptor Antagonists
  • Hypnotics and Sedatives
  • Receptors, Dopamine D1
  • Receptors, Dopamine D2
  • Salicylamides
  • Raclopride
  • Haloperidol
  • Dopamine
Topics
  • Animals
  • Basal Ganglia Diseases (chemically induced, physiopathology)
  • Behavior, Animal (drug effects)
  • Benzazepines (pharmacology)
  • Cebus
  • Dopamine (physiology)
  • Dopamine D2 Receptor Antagonists
  • Dose-Response Relationship, Drug
  • Female
  • Grooming (drug effects)
  • Haloperidol (adverse effects)
  • Hypnotics and Sedatives (pharmacology)
  • Male
  • Motor Activity (drug effects)
  • Raclopride
  • Receptors, Dopamine D1 (agonists, antagonists & inhibitors)
  • Receptors, Dopamine D2 (agonists)
  • Salicylamides (pharmacology)
  • Stereotyped Behavior (drug effects)
  • Substance Withdrawal Syndrome (psychology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: